DLA Piper advises DCVC Bio as lead investor in 17 million USD A-series investment round in BioPhero ApS

DLA Piper Denmark advises California-based venture capital fund, DCVC Bio, in a 17 million USD A-series investment round in the Danish-based biotech company BioPhero ApS.

DCVC Bio acted as the lead investor in the investment round with participation from new investor FMC Venture and existing investors Syngenta Group Ventures and Novo Holdings.

BioPhero develops and produces active pheromone ingredients for the agricultural sector, and the investment will accelerate the company’s mission to ramp up production and sales for the growing market.

DCVC Bio was advised by DLA Piper Denmark with Andreas Brasch-Thomsen and Niels Ankerstjerne Sloth leading the team.

Read more about the investment here.